Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio
Waters Corporation (NYSE:WAT) has acquired Halo Labs, a company specializing in imaging technologies for particle analysis in therapeutic products. The acquisition brings Halo's Aura™ platform, which offers full spectrum particle analysis capabilities complementary to Waters' existing Wyatt Technology™ Portfolio.
The Aura platform's key advantage lies in its ability to detect translucent process impurities in CAR T-cell therapies that are typically undetectable through standard methods. This technology will be integrated into Waters' large molecule development and QA/QC processes, enhancing their analytical capabilities for biopharmaceutical applications.
The acquisition is expected to have a negligible impact on Waters' income statement over the next 12 months.
Waters Corporation (NYSE:WAT) ha acquisito Halo Labs, un'azienda specializzata in tecnologie di imaging per l'analisi delle particelle nei prodotti terapeutici. L'acquisizione include la piattaforma Aura™ di Halo, che offre capacità di analisi delle particelle a spettro completo, complementari al portafoglio Wyatt Technology™ già esistente di Waters.
Il principale vantaggio della piattaforma Aura risiede nella sua capacità di rilevare impurità traslucide nei processi delle terapie CAR T-cell, solitamente non individuabili con metodi standard. Questa tecnologia sarà integrata nei processi di sviluppo e controllo qualità (QA/QC) delle molecole grandi di Waters, migliorando le capacità analitiche per le applicazioni biofarmaceutiche.
L'acquisizione dovrebbe avere un impatto trascurabile sul conto economico di Waters nei prossimi 12 mesi.
Waters Corporation (NYSE:WAT) ha adquirido Halo Labs, una empresa especializada en tecnologías de imagen para el análisis de partículas en productos terapéuticos. La adquisición incluye la plataforma Aura™ de Halo, que ofrece capacidades de análisis de partículas de espectro completo, complementarias al portafolio Wyatt Technology™ existente de Waters.
La principal ventaja de la plataforma Aura radica en su habilidad para detectar impurezas translúcidas en procesos de terapias con células CAR T, que normalmente no se detectan con métodos estándar. Esta tecnología se integrará en los procesos de desarrollo y control de calidad (QA/QC) de moléculas grandes de Waters, mejorando sus capacidades analíticas para aplicaciones biofarmacéuticas.
Se espera que la adquisición tenga un impacto insignificante en el estado de resultados de Waters durante los próximos 12 meses.
Waters Corporation (NYSE:WAT)는 치료 제품의 입자 분석을 위한 이미징 기술을 전문으로 하는 Halo Labs를 인수했습니다. 이번 인수를 통해 Halo의 Aura™ 플랫폼이 Waters의 기존 Wyatt Technology™ 포트폴리오를 보완하는 전 스펙트럼 입자 분석 기능을 제공하게 되었습니다.
Aura 플랫폼의 주요 장점은 일반적인 방법으로는 감지할 수 없는 CAR T 세포 치료제 내의 반투명 공정 불순물을 감지할 수 있다는 점입니다. 이 기술은 Waters의 대분자 개발 및 품질 관리(QA/QC) 프로세스에 통합되어 바이오제약 응용 분야에서 분석 역량을 강화할 것입니다.
이번 인수는 향후 12개월 동안 Waters의 손익계산서에 미미한 영향을 미칠 것으로 예상됩니다.
Waters Corporation (NYSE:WAT) a acquis Halo Labs, une entreprise spécialisée dans les technologies d'imagerie pour l'analyse des particules dans les produits thérapeutiques. Cette acquisition inclut la plateforme Aura™ de Halo, qui offre des capacités d'analyse complète des particules, venant compléter le portefeuille Wyatt Technology™ déjà existant chez Waters.
Le principal avantage de la plateforme Aura réside dans sa capacité à détecter des impuretés translucides dans les processus des thérapies CAR T-cell, généralement indétectables par les méthodes standards. Cette technologie sera intégrée aux processus de développement et de contrôle qualité (QA/QC) des macromolécules de Waters, renforçant ainsi leurs capacités analytiques pour les applications biopharmaceutiques.
Cette acquisition devrait avoir un impact négligeable sur le compte de résultat de Waters au cours des 12 prochains mois.
Waters Corporation (NYSE:WAT) hat Halo Labs übernommen, ein Unternehmen, das sich auf Bildgebungstechnologien zur Partikelanalyse in therapeutischen Produkten spezialisiert hat. Durch die Übernahme wird die Aura™ Plattform von Halo, die umfassende Partikelanalysefähigkeiten bietet und das bestehende Wyatt Technology™ Portfolio von Waters ergänzt, integriert.
Der Hauptvorteil der Aura-Plattform liegt in ihrer Fähigkeit, transluzente Prozessverunreinigungen in CAR-T-Zelltherapien zu erkennen, die mit Standardmethoden normalerweise nicht nachweisbar sind. Diese Technologie wird in die Entwicklung und die QA/QC-Prozesse großer Moleküle von Waters integriert und verbessert so die analytischen Fähigkeiten für biopharmazeutische Anwendungen.
Es wird erwartet, dass die Übernahme in den nächsten 12 Monaten kaum Auswirkungen auf die Gewinn- und Verlustrechnung von Waters haben wird.
- Acquisition expands Waters' analytical capabilities in the growing cell and gene therapy market
- Halo Labs' technology complements Waters' existing Wyatt Technology Portfolio
- Technology enables detection of previously undetectable impurities in CAR T-cell therapies
- Strengthens Waters' position in specialized analytical technologies for biopharma
- Negligible financial impact expected in the first 12 months
- Integration costs and challenges may arise during technology incorporation
Insights
Waters' acquisition of Halo Labs strengthens its position in the high-growth biologics testing market with complementary particle analysis technology.
Waters Corporation's acquisition of Halo Labs represents a strategic expansion of its analytical capabilities for biological therapeutics, particularly in the rapidly growing cell and gene therapy space. The Aura™ platform from Halo Labs provides specialized imaging technology for detecting and analyzing particles in therapeutic products that complements Waters' existing Wyatt Technology portfolio of light scattering detection solutions.
The acquisition addresses a critical need in CAR T-cell therapy development, where Halo's technology can detect translucent process impurities that remain invisible to standard methods. This capability is particularly valuable for quality control during manufacturing of advanced therapies, where particle contamination can impact both efficacy and safety.
From a competitive standpoint, this move strengthens Waters' position in the biopharma analytical testing market, particularly for large molecule therapies which represent the fastest-growing segment of the pharmaceutical industry. By integrating Halo's technology into existing Waters workflows, the company can offer more comprehensive solutions for both drug development and quality assurance/quality control processes.
The press release indicates the acquisition will have a "negligible impact" on Waters' income statement over the next 12 months, suggesting this is a relatively small acquisition focused on technology capabilities rather than immediate revenue contribution. This aligns with Waters' strategy of building specialized analytical capabilities that support the full lifecycle of biopharmaceutical products, from early research through manufacturing.
For investors, this acquisition represents Waters' continued commitment to expanding its footprint in high-growth therapeutic areas like cell and gene therapy, positioning the company to benefit from the projected expansion of these markets over the coming decade.
The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy, detecting these translucent process impurities that are currently undetectable by standard methods. By acquiring this innovative company, Waters will be able to integrate this emerging technology into new and existing large molecule development and QA/QC, giving a key value-add to customers while accelerating the Company's growth into analytical and bioprocessing testing for large molecule therapies.
"Adding the innovative low-sample-volume, high-throughput technology from Halo Labs provides analysis for a broad range of sample types and volumes, enabling earlier insights during therapy development and greater safety during manufacturing," said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation. "With the rapid growth of treatments like CAR T-cell therapies, we are investing in the innovation our customers need. Together with our existing Wyatt Technology product lines, this acquisition enhances our leadership position in specialized analytical technologies for emerging biopharma therapies."
"We are thrilled to join forces with Waters, a company that shares our values of purposeful innovation and customer focus," said Rick Gordon, Chief Executive Officer, Halo Labs. "This combination accelerates our vision to expand our platform's reach, enhancing therapeutic development and production while maintaining our unwavering commitment to drug quality and safety. We look forward to driving more groundbreaking advancements that benefit patients worldwide."
Today's acquisition of Halo Labs is expected to have a negligible impact on the Company's income statement over the following 12 months.
About Halo Labs
Halo Labs is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation, stability, and product quality control tools for aggregate and subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Biopharmaceutical companies around the globe depend on Halo Labs for unprecedented insights into their drug products.
About Waters Corporation
Waters Corporation (NYSE:WAT), is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.
Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation.
Contact:
Laura Borland
Senior Director, Business Unit Communications
Waters Corporation
laura_borland@waters.com
+1.302.367.6958
View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-acquires-halo-labs-expanding-biological-analysis-portfolio-302461826.html
SOURCE Waters Corporation
FAQ
What company did Waters Corporation (WAT) acquire in May 2025?
How will the Halo Labs acquisition impact Waters' (WAT) financial performance?
What is the main technology acquired in Waters' (WAT) Halo Labs acquisition?
How does Halo Labs' technology complement Waters' (WAT) existing portfolio?
What market segment will Waters (WAT) strengthen through the Halo Labs acquisition?
